Table 1 Clinical characteristics of case and control patients
Characteristics | Cases (n = 32) | Controls (n = 64) | P value |
|---|---|---|---|
Age (yr), mean ± SD | 81 ± 5 | 81 ± 5 | NS |
Gender, M/F | 14/18 | 28/36 | NS |
PT-INR | |||
Median PT-INR(Q1,Q3) | 2.62 (1.97, 5.30) | 1.75 (1.52, 2.14) | <0.05 |
≤1.49, n (%) | 5 (16) | 15 (24) | NS |
1.50 to 1.99, n (%) | 3 (9) | 29 (45) | <0.05 |
2.00 to 2.49, n (%) | 5 (16) | 13 (20) | NS |
2.50 to 2.99, n (%) | 4 (12) | 6 (9) | NS |
≥3.00, n (%) | 15 (47) | 1 (2) | <0.05 |
eGFR (mL/min/1.73 m2), mean ± SD | 43 ± 27 | 49 ± 15 | NS |
CHADS2 score, mean ± SD | 3 ± 1 | 3 ± 1 | NS |
Congestive heart failure, n (%) | 19 (59) | 19 (30) | <0.05 |
Hypertension, n (%) | 22 (69) | 50 (78) | NS |
Diabetes, n (%) | 5 (16) | 21 (33) | NS |
Stroke/TIA, n (%) | 16 (50) | 23 (36) | NS |
HAS-BLED score, mean ± SD | 3 ± 1 | 3 ± 1 | NS |
Impaired renal function, n (%) | 7 (22) | 3 (5) | <0.05 |
Impaired liver function, n (%) | 4 (13) | 3 (5) | NS |
Stroke, n (%) | 14 (44) | 22 (34) | NS |
History of bleeding, n (%) | 10 (31) | 14 (22) | NS |
Labile PT-INR, n (%) | 2 (6) | 19 (30) | NS |
Antiplatelet or NSAID, n (%) | 12 (38) | 24 (38) | NS |
Alcohol consumption, n (%) | 1 (3) | 4 (6) | NS |